58 140

Cited 0 times in

성장인자수용체-2 양성 유방암 조직에서 표적치료 전후의 성장인자수용체군 발현양상

Other Titles
 Expression of growth factor receptor family before and after targeted therapy in human epidermal growth factor receptor-2 positive breast cancer tissues 
 박세호  ;  고영신  ;  구자승  ;  손주혁  ;  김승일  ;  박병우 
 Korean Journal of Clinical Oncology (대한임상종양학회지), Vol.11(1) : 12-19, 2015 
Journal Title
 Korean Journal of Clinical Oncology  (대한임상종양학회지) 
Issue Date
Purpose: This study aimed to compare expression of human epidermal growth factor receptor (HER) family and insulin-like growth factor-1 receptor (IGF-1R) before and after targeted therapy in HER-2 positive breast cancers. Methods: Epidermal growth factor receptor (EGFR), HER-3, HER-4, and IGF-1R were immunohistochemically determined using pairwise archives tumor blocks of 28 patients received chemotherapy and HER-2 directed therapy between January 2007 and December 2011. Of them, 5 good responders achieved a pathologic complete response after neoadjuvant therapy and 23 poor responders experienced disease progression or metastasis even HER-2 targeted therapy. Expression of biomarkers was compared using chi-square test. Results: Stage II, III, and IV was 14 (50.0%), 11 (39.3%), and 3 (10.7%) patients, respectively. Hormone receptors-positive tumors were 15 (53.6%) patients and 9 (32.1%) patients received tyrosine kinase inhibitors with or without trastuzumab. Positive expression of initial EGFR, HER-3, HER-4, and IGF-1R was determined in 15 (53.6%), 11 (39.3%), 22 (78.6%), and 14 (50.0%) patients, respectively. Although there was no statistical significance, good responders showed a higher proportion of positive HER-3 expression. Among 23 poor responders, growth factor receptors family expression showed a trend of concordant results, however, unpredictively certain patients demonstrated discordant results between before and after targeted therapy. Conclusion: Unpredicted correlation of growth factor receptors family expression suggested that complex and personalized resistance mechanisms may be involved to HER-2 directed therapy. However, HER-3 expression might be associated with responsiveness to HER-2 targeted therapy. It would be important to develop diagnostic and therapeutic strategies for overcoming resistance to HER-2 targeted therapy.
Appears in Collections:
1. Journal Papers (연구논문) > 1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실)
1. Journal Papers (연구논문) > 1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실)
1. Journal Papers (연구논문) > 1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실)
Yonsei Authors
구자승(Koo, Ja Seung) ; 김승일(Kim, Seung Il) ; 박병우(Park, Byeong Woo) ; 박세호(Park, Se Ho) ; 손주혁(Sohn, Joo Hyuk)
사서에게 알리기
Files in This Item:
T201502228.pdf Download
RIS (EndNote)
XLS (Excel)


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.